Andrew Cittadine - Sep 30, 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-Fact
Stock symbol
MNPR
Transactions as of
Sep 30, 2022
Transactions value $
-$1,810
Form type
4
Date filed
10/3/2022, 07:42 PM
Previous filing
Jul 1, 2022
Next filing
Nov 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +4.06K +76.47% 9.38K Sep 30, 2022 Direct F1
transaction MNPR Common Stock Tax liability -$1.81K -1.19K -12.7% $1.52 8.19K Sep 30, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -4.06K -7.14% $0.00 52.8K Sep 30, 2022 Common Stock 4.06K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.